PMID- 33764511 OWN - NLM STAT- MEDLINE DCOM- 20210927 LR - 20210927 IS - 1365-2141 (Electronic) IS - 0007-1048 (Linking) VI - 193 IP - 6 DP - 2021 Jun TI - Minimal residual disease level determined by flow cytometry provides reliable risk stratification in adults with T-cell acute lymphoblastic leukaemia. PG - 1096-1104 LID - 10.1111/bjh.17424 [doi] AB - Minimal residual disease (MRD) is an important independent prognostic factor for relapse and survival in acute lymphoblastic leukaemia (ALL). Compared with adult B-cell ALL, reports of adult T-cell ALL (T-ALL) MRD have been scarce and mostly based on molecular methods. We evaluated the prognostic value of multiparameter flow cytometry (FCM)-based MRD at the end of induction (EOI-MRD). The present retrospective study included 94 adult patients with T-ALL. MRD was detected by six- to eight-colour FCM. Patients who were EOI-MRD positive had a higher cumulative incidence of relapse (CIR) (87.6% vs. 38.8%, P = 0.0020), and a lower relapse-free survival (RFS) (5.4% vs. 61.0%, P = 0.0005) and overall survival (OS) (32.7% vs. 69.7%, P < 0.0001) than those who were EOI-MRD negative. Moreover, for patients who received allogeneic haematopoietic stem cell transplantation (allo-HSCT) at their first remission, EOI-MRD positivity was predictive of post-transplant relapse (2-year CIR: 68.2% vs. 4.0%, P = 0.0003). Multivariate analysis showed that EOI-MRD was an independent prognostic factor for CIR [hazard ratio (HR) 2.139, P = 0.046], RFS (HR 2.125, P = 0.048) and OS (HR 2.987, P = 0.017). In conclusion, EOI-MRD based on FCM was an independent prognostic factor for relapse and survival in adult T-ALL. For patients who underwent HSCT, EOI-MRD could be used to identify patients with a high risk of relapse after allo-HSCT. CI - (c) 2021 British Society for Haematology and John Wiley & Sons Ltd. FAU - Wang, Huanping AU - Wang H AUID- ORCID: 0000-0003-4080-3329 AD - Department of Hematology, School of Medicine, the First Affiliated Hospital, Zhejiang University, Hangzhou, China. AD - Zhejiang Province Key Laboratory of Hematology Oncology Diagnosis and Treatment, Hangzhou, China. FAU - Zhou, Yile AU - Zhou Y AD - Department of Hematology, School of Medicine, the First Affiliated Hospital, Zhejiang University, Hangzhou, China. FAU - Huang, Xin AU - Huang X AD - Department of Hematology, School of Medicine, the First Affiliated Hospital, Zhejiang University, Hangzhou, China. FAU - Zhang, Yi AU - Zhang Y AUID- ORCID: 0000-0003-3625-2288 AD - Department of Hematology, School of Medicine, the First Affiliated Hospital, Zhejiang University, Hangzhou, China. FAU - Qian, Jiejing AU - Qian J AD - Department of Hematology, School of Medicine, the First Affiliated Hospital, Zhejiang University, Hangzhou, China. FAU - Li, Jianhu AU - Li J AD - Department of Hematology, School of Medicine, the First Affiliated Hospital, Zhejiang University, Hangzhou, China. FAU - Li, Chenying AU - Li C AD - Department of Hematology, School of Medicine, the First Affiliated Hospital, Zhejiang University, Hangzhou, China. FAU - Li, Xueying AU - Li X AUID- ORCID: 0000-0002-9609-1984 AD - Department of Hematology, School of Medicine, the First Affiliated Hospital, Zhejiang University, Hangzhou, China. FAU - Lou, Yinjun AU - Lou Y AD - Department of Hematology, School of Medicine, the First Affiliated Hospital, Zhejiang University, Hangzhou, China. FAU - Zhu, Qiaoyun AU - Zhu Q AD - Central Laboratory, School of Medicine, the First Affiliated Hospital, Zhejiang University, Hangzhou, China. FAU - Huang, Yujie AU - Huang Y AD - Key Laboratory of Drug Clinical Research and Evaluation Technology of Zhejiang Province, School of Medicine, the First Affiliated Hospital, Zhejiang University, Hangzhou, China. FAU - Meng, Haitao AU - Meng H AD - Department of Hematology, School of Medicine, the First Affiliated Hospital, Zhejiang University, Hangzhou, China. FAU - Yu, Wenjuan AU - Yu W AD - Department of Hematology, School of Medicine, the First Affiliated Hospital, Zhejiang University, Hangzhou, China. FAU - Tong, Hongyan AU - Tong H AUID- ORCID: 0000-0001-5603-4160 AD - Department of Hematology, School of Medicine, the First Affiliated Hospital, Zhejiang University, Hangzhou, China. FAU - Jin, Jie AU - Jin J AUID- ORCID: 0000-0002-8166-9915 AD - Department of Hematology, School of Medicine, the First Affiliated Hospital, Zhejiang University, Hangzhou, China. AD - Zhejiang Province Key Laboratory of Hematology Oncology Diagnosis and Treatment, Hangzhou, China. FAU - Zhu, Hong-Hu AU - Zhu HH AD - Department of Hematology, School of Medicine, the First Affiliated Hospital, Zhejiang University, Hangzhou, China. AD - Zhejiang Province Key Laboratory of Hematology Oncology Diagnosis and Treatment, Hangzhou, China. AD - Zhejiang University Cancer Center, Hangzhou, China. AD - Zhejiang Laboratory for Systems and Precision Medicine, Zhejiang University Medical Center, Hangzhou, China. LA - eng PT - Journal Article DEP - 20210325 PL - England TA - Br J Haematol JT - British journal of haematology JID - 0372544 SB - IM MH - Adolescent MH - Adult MH - Aged MH - Allografts MH - Disease-Free Survival MH - Female MH - *Flow Cytometry MH - *Hematopoietic Stem Cell Transplantation MH - Humans MH - Male MH - Middle Aged MH - Neoplasm, Residual MH - *Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/blood/mortality/therapy MH - Retrospective Studies MH - Risk Assessment MH - Survival Rate OTO - NOTNLM OT - T-cell acute lymphoblastic leukaemia OT - adult OT - flow cytometry OT - minimal residual disease OT - risk stratification EDAT- 2021/03/26 06:00 MHDA- 2021/09/28 06:00 CRDT- 2021/03/25 12:55 PHST- 2020/12/31 00:00 [received] PHST- 2021/02/28 00:00 [accepted] PHST- 2021/03/26 06:00 [pubmed] PHST- 2021/09/28 06:00 [medline] PHST- 2021/03/25 12:55 [entrez] AID - 10.1111/bjh.17424 [doi] PST - ppublish SO - Br J Haematol. 2021 Jun;193(6):1096-1104. doi: 10.1111/bjh.17424. Epub 2021 Mar 25.